Lupus & antiphospholipid syndrome
Eltrombopag in the treatment of immune thrombocytopenia secondary to systemic lupus erythematosus (SLE): A double-edged sword
Authors' conclusion
Eltrombopag was associated with platelet response in this cohort. Thrombosis was numerically more common in aPL-positive patients, but the small sample and imprecise estimate preclude conclusions about its independent contribution. Without a comparator group, whether these events reflect eltrombopag, the prothrombotic milieu of SLE and aPL antibodies, or their interaction cannot be determined.
Study context
- Population
- Patients with SLE-associated thrombocytopenia treated with eltrombopagpatients with SLE-associated thrombocytopenia treated with eltrombopag
- Participants
- 23 patients
- Outcome
- Sustained platelet response (≥50 ×109/L at last follow-up) and occurrence of thrombotic events
- Follow-up
- Last
Main finding
As reported in the abstract
Sustained platelet response
65.2%
Thrombotic events
8 patients
34.8%
Arterial events, share of thrombotic cases
50%
Observational data: associations, not effects.
Further findings
| Outcome | aPL-positive | aPL-negative | OR (95% CI) | P value | |
|---|---|---|---|---|---|
| Thrombotic events by aPL status (exploratory)Did not reach statistical significance | 41.7% | 27.3% | 1.90 (0.33–11.01) | P = 0.667 | |
| 0.050.21520Odds ratio (log scale) |
Weaned off corticosteroids
- Successfully weaned off corticosteroids
- 21.7%
Time to thrombosis
- Median time to thrombosis
- 5.5 months
- Thrombosis occurred across a range of platelet counts and was not consistently associated with thrombocytosis
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →